Haleos Labs: Credit Ratings Reaffirmed by Infomerics
Haleos Labs' credit ratings reaffirmed by Infomerics. Long-term rating: IVR BBB/Positive, Short-term: IVR A3+. Total bank facilities: ₹116.01 Cr. Mahi Drugs' long-term rating: IVR BB+/Stable. Total bank facilities: ₹20.75 Cr. Ratings valid until May 20, 2027.
Improved or reaffirmed credit ratings can positively influence borrowing costs and access to finance, which is important for ongoing operations and potential expansion.
The reaffirmation of credit ratings by a reputable agency like Infomerics is a positive development, indicating stable creditworthiness and financial health.
Haleos Labs Limited announced that Infomerics Valuation and Rating Limited has reaffirmed the credit ratings for the company's fund-based and non-fund-based bank facilities, as well as those of its material subsidiary, Mahi Drugs Private Limited. The ratings were reaffirmed on May 21, 2026. For Haleos Labs, the total bank loan facilities rated amount to ₹116.01 Crore, an enhancement from the previously regulated ₹81.86 Crore. The long-term rating has been reaffirmed as IVR BBB/Positive, and the short-term rating as IVR A3+. These ratings are typically valid for one year from the rating committee date, which was May 20, 2027.
For Mahi Drugs Private Limited, the total bank loan facilities rated are ₹20.75 Crore, an enhancement from ₹10.83 Crore. The long-term rating has been reaffirmed as IVR BB+/Stable. The ratings are subject to surveillance and review by Infomerics and are based on the operational and financial performance of the companies for FY25 and 9MFY26. The company has also provided details of the rated facilities in Annexure I and information on regulators in Annexure II.
What to do with a filing like this
HALEOS LABS LIMITED filed this with the NSE as a statutory disclosure, categorised under credit ratings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by HALEOS LABS LIMITED. Read the original for the full detail.